Akebia Therapeutics

Historical price data

Founded in 2007, Akebia Therapeutics has established itself as a leader in the renal community, dedicated to bettering the lives of those impacted by kidney disease. The company has built a fully integrated organization with a nephrology-focused commercial team and a robust R&D engine centered on oral HIF-PH inhibitors. With two FDA-approved products and a late-stage candidate, vadadustat, in development for anemia due to chronic kidney disease, Akebia aims to address significant unmet needs and set new standards of care.

Oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) that mimic the body's physiological response to low oxygen, stimulating endogenous erythropoietin production and regulating iron metabolism to treat anemia and other conditions.

40 drugs in pipeline, 13 in Phase 3

Total raised: $269M

Akebia faces competition from large pharma companies marketing injectable ESAs (Amgen, J&J), other developers of oral HIF-PHIs (GSK, FibroGen/AstraZeneca), and providers of IV iron and phosphate binders. Its differentiation is based on deep HIF expertise, an oral therapy modality, and a focused, integrated renal commercial and development organization.